Navigation Links
Sunesis Reports Financial Results for the First Quarter 2009
Date:5/6/2009

e in events, conditions or circumstances on which any such statements are based.

    Investor Contact:                      Media Contact:
    Sunesis Pharmaceuticals, Inc.          Sunesis Pharmaceuticals, Inc.
    Eric Bjerkholt                         Dan Weinseimer
    650-266-3717                           650-266-3739

                        SUNESIS PHARMACEUTICALS, INC.
                    CONDENSED CONSOLIDATED BALANCE SHEETS

                                               March 31,   December 31,
                                                 2009          2008
                                              ----------   -----------
    ASSETS                                    (unaudited)    (Note 1)
    Current assets:
         Cash and cash equivalents             $4,280,363    $6,296,942
         Marketable securities                          -     4,321,844
         Prepaids and other current assets        763,074       934,429
                                               ----------   -----------
    Total current assets                        5,043,437    11,553,215
    Property and equipment, net                   501,751       612,241
    Assets held-for-sale                           50,427       470,547
    Deposits and other assets                      96,824       147,826
                                               ----------   -----------
    Total assets                               $5,692,439   $12,783,829
                                               ==========   ===========

    LIABILITIES AND STOCKHOLDERS' (DEFICIT)
     EQUITY
    Current liabilities:
         Accounts payable and other accrued
          liabilities                          $1,994,735    $2,150,980
         Accrued clinical expense               1,794,154     1,865,773
         Accrued compensation                     845,649       537,215
         Accrued restructuring charges      
'/>"/>
SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
2. Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350
3. Sunesis Pharmaceuticals SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology
4. Sunesis Pharmaceuticals to Present at Healthcare Investor Conferences in March
5. Sunesis Pharmaceuticals Presents Nonclinical Data on SNS-595 at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
7. Sunesis Pharmaceuticals to Present at the Collins Stewart Fourth Annual Growth Conference
8. Sunesis Pharmaceuticals Announces Up To $43.5 Million Financing
9. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
10. Haemacure Reports Third Quarter 2007 Results
11. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... LEXINGTON, Ky (Sept. 17, 2014) -- Two independent ... PhD, of the University of Kentucky, and Charles ... published important studies exploring the role that a ... cardiovascular disease. , According to Whiteheart, previous genome-wide ... as a factor that regulates a protein called ...
(Date:9/18/2014)... release is available in German . ... host strategy not to fight a pathogen tooth and nail, but ... term. One key feature of tolerance is that the disease only ... host carries a high pathogen load. , Roland Regoes, a senior ... this approach to HIV. He set about investigating whether there are ...
(Date:9/18/2014)... CAMBRIDGE, Massachusetts, U.S.A., September 18, 2014 -- BGI ... sequencing service to Denmark-based DLF-Trifolium and the Department ... University in an effort to develop a series ... genomic selection (GS) methods. , GS is a ... contrast to the traditional QTL-based selection, uses information ...
(Date:9/18/2014)... September 18, 2014 CRDF Global ... first ever digital edition – rich with videos, ... of how CRDF Global empowers scientists and innovators ... of government, corporate, foundation and individual supporters, CRDF ... innovators in research, training and entrepreneurship. , The ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Research conducted ... Allegheny Health Network has documented improved survival ... surgical removal of the tumors along with stereotactic radiosurgery. ... of ASTRO (American Society for Radiation Oncology) ... uses numerous precisely focused radiation beams to treat tumors ...
Breaking Medicine News(10 mins):Health News:University of Kentucky research explores STXBP5 gene and its role in blood clotting 2Health News:Withdrawal from the evolutionary race 2Health News:Withdrawal from the evolutionary race 3Health News:BGI Tech, DLF-Trifolium A/S, and Aarhus University applying genomic selection methods 2Health News:CRDF Global Launches Media-Rich Digital Edition of Annual Report, Tells Story of Empowering Scientists and Innovators around the World in 2013 2Health News:Allegheny Health Network Study Shows Improved Survival in Patients with Metastatic Brain Cancer Who Undergo Surgical Excision Combined with Stereotactic Radiosurgery 2Health News:Allegheny Health Network Study Shows Improved Survival in Patients with Metastatic Brain Cancer Who Undergo Surgical Excision Combined with Stereotactic Radiosurgery 3
... to detect suspicious activity in airports, stadiums and other ... researcher who invented them to find and measure potentially ... professor of Computer Science and one of the world,s ... computer imaging, has received $400,000 from the National Institutes ...
... about the importance of eye assessments for babies during June,s ... 2 When should a parent schedule a comprehensive eye ... at 6 months, the average baby has reached a number ... the first eye and vision assessment. , , According ...
... for space headache to be established as a new ... astronauts, published in the June issue of Cephalalgia ... headaches are normally caused by space motion sickness, after ... no connection. "Our research shows that space flights ...
... device will facilitate single port access laparoscopic surgery , ... privately held biomaterials-based medical device company, announced today that ... and Drug Administration to market the InnoPort(TM) to facilitate ... The InnoPort is inserted into the abdomen to perform ...
... , - Free health clinics facing crisis of increasing demand, ... hand in helping make donation possible , , - ... banks in December , , RICHMOND, Va., June 2 ... announced today it is donating $1 million to free health ...
... ... at trial, and bring Attorneys state of the art fall prevention and protection training. ... (PRWEB) June ... settlements, assist representation at trial, and bring Attorneys state of the art fall prevention ...
Cached Medicine News:Health News:UCF researcher developing computer program to detect, measure brain tumors 2Health News:Make Sure Your Baby is Seeing the Most Important Things in His World 2Health News:Make Sure Your Baby is Seeing the Most Important Things in His World 3Health News:Make Sure Your Baby is Seeing the Most Important Things in His World 4Health News:Make Sure Your Baby is Seeing the Most Important Things in His World 5Health News:Researchers call for new space headache category following astronauts' survey 2Health News:Innovia Receives FDA Clearance For The InnoPort(TM) 2Health News:Dominion Helps Communities by Donating $1 Million to Health Clinics 2Health News:Dominion Helps Communities by Donating $1 Million to Health Clinics 3Health News:Dominion Helps Communities by Donating $1 Million to Health Clinics 4Health News:Fall Prevention/Protection - Slip and Fall Accredited Training for Legal Practices 2
(Date:9/18/2014)... , Sept. 18, 2014 This BCC Research report ... of major players, market growth and size, and opportunities for ... and revenue through 2018. Patent analysis in the report focuses ... the U.S., Europe and ... - Define and discuss the global medical device technologies market. ...
(Date:9/18/2014)... , Sept. 18, 2014  Iliad Neurosciences, Inc., a ... diagnosing and treating Autism Spectrum Disorders (ASD) announced today ... with The Research Foundation for The State University of ... provide a new biomarker to identify an abnormality in ... ASD. This biomarker is expected to be available for ...
(Date:9/18/2014)... Pharma IQ, after huge demand ... Countdown calendar to cover the years 2014 - 2018 ... shows the serialisation requirements around the globe and the ... For companies dealing with international markets, serialisation ... they will have to comply with new regulations coming ...
Breaking Medicine Technology:Medical Devices: Technologies and Global Markets 2Medical Devices: Technologies and Global Markets 3Medical Devices: Technologies and Global Markets 4Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 2Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 3Pharma IQ Displays Worldwide Serialisation Deadlines in their 2014 - 2018 Countdown Calendar 2
... Intellect Neurosciences, Inc. (OTCBB: ILNS), a biopharmaceutical company ... therapeutic agents for the treatment of Alzheimer,s and ... filed a response and request for continued examination ... 10/084,380, one of several applications pending in the ...
... VIEW, Calif., Nov. 3, 2011 VIVUS, Inc. (NASDAQ: ... chief financial officer, will present an overview of the ... The VIVUS presentation will take place at the ... at 9:30 a.m. MST.  A live webcast and 30-day ...
Cached Medicine Technology:Intellect Neurosciences Responds to Official Action by United States Patent and Trademark Office in Relation to its ANTISENILIN® Alzheimer's Patent Application 2Intellect Neurosciences Responds to Official Action by United States Patent and Trademark Office in Relation to its ANTISENILIN® Alzheimer's Patent Application 3
The MULTI-LINK RX PENTA Coronary Stent Systems with new ACCESS-LINK Stent Design are indicated for improving coronary luminal diameter....
Now available in 2.75-mm diameters, the S660 small vessel coronary stent expands your treatment options for accurate sizing and precision stenting....
The MULTI-LINK PIXEL Coronary Stent System was designed to address the challenges of small vessel treatment in patients with abrupt or threatened abrupt closure (ATC)....
... EVS has an ergonomic stapler ... mechanism which requires a single ... locks onto the target vessel ... site before, during and after ...
Medicine Products: